PhRMA sued the Trump administration over the Medicare GLOBE pilot, arguing the most-favored nation framework exceeds Medicare’s statutory authority for Part B drug pricing. PhRMA said the program would force pricing alignment to peer countries, but the administration’s exemptions for many companies reduce expected direct impact.